StreetAlpha.app
Home › Stocks › CELC

Celcuity Inc. (CELC)

Healthcare
$53.35
▼ −5.26%
LAST CLOSE · NOV 20

Celcuity is a Minneapolis biotechnology company developing gedatolisib, a cancer drug candidate for breast and prostate cancer patients. It last closed at $53.35 on Nov 20, down 5.26% on the day. The next earnings report for CELC is expected around Wed, Mar 24, 2027, after the close. For the quarter ended Sep 2026, CELC reported EPS of -$1.33. Over its last 8 reports the stock moved an average of 3.7% the session after earnings. Over the last 12 months CELC insiders bought $0 of stock on the open market and sold $327.6M, according to SEC Form 4 filings.

AI Auto Pilots
Is CELC in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CELC.

Key Stats

Last 12 months
Results
Net income
−$256.0M
EPS (diluted)
−$4.72
Free cash flow
−$213.5M
Valuation
Market cap
$2.6B
49.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$178.2M
At Sep 30
Debt
$0
At Sep 30
Shareholder equity
−$74.0M
Shares outstanding
49.1M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$29.6M−$29.6MFY2021FY2022: −$40.4M−$40.4MFY2022FY2023: −$63.8M−$63.8MFY2023FY2024: −$111.8M−$111.8MFY2024FY2025: −$177.0M−$177.0MFY2025

From CELC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 24
Estimated date · After the close
Reported EPS
-$1.33
Quarter ended Sep 2026
Year ago EPS
-$0.92
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.87Dec '24Mar 2025: -$0.86Mar '25Jun 2025: -$1.04Jun '25Sep 2025: -$0.92Sep '25Dec 2025: -$0.98Dec '25Mar 2026: -$0.97Mar '26Jun 2026: -$1.44Jun '26Sep 2026: -$1.33Sep '26Latest -$1.33
Revenue by quarter
Not enough quarters on file yet.
How CELC moved after its last 8 reports
Average move the session after a report ±3.7%
Nov 5, 2026After the close+4.3%
Aug 13, 2026After the close+6.2%
May 14, 2026After the close+2.2%
Mar 25, 2026After the close+4.2%
Nov 12, 2025After the close+1.0%
Aug 14, 2025After the close−0.2%
May 14, 2025After the close−3.1%
Mar 31, 2025After the close−8.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CELCStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CELC
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CELC

Technical Analysis

CELC · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 21% below its 20 day and 30% below its 50 day average. It is 82% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), near oversold. The nearest support is the 52 week low at $53.20, and the nearest resistance the Pivot at $54.52.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.7%/day
Key levels
$151.0252 week high+183.1%
$97.15200 day average+82.1%
$81.21100 day average+52.2%
$72.24Swing high (Nov 9)+35.4%
$69.1950 day average+29.7%
$64.6420 day average+21.2%
$55.83Pivot R1+4.6%
$54.52Pivot+2.2%
$53.35Last close
$53.2052 week low−0.3%
$52.03Pivot S1−2.5%
Indicators
RSI (14)30.08Weak, oversold below 30Neutral
MACD-3.58Below its signal lineBearish
Stochastic3.6Near the bottom of its rangeOversold
ADX (14)21.9Weak trend
Williams %R-99.2Oversold below −80, overbought above −20Oversold
CCI (20)-176.1Oversold below −100, overbought above 100Oversold
Rate of change−20.1%Change over 10 sessionsBearish
ATR (14)$4.09Typical daily range, 7.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CELC

What happened before

See how CELC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CELC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CELC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CELCHow many large options trades hit CELC, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CELC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲162 buying vs 129 selling
  • ▲Held by funds +2.7 pts
  • ▼Funds holding -7
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding270277−2.5%
In funds' top 101314−7.1%
Held by funds118.8%116.1%+2.7 pts
New / increased50 / 11260 / 108−3.6%
Reduced / sold out73 / 5680 / 63−9.8%
Put/call ratio0.543.70−85.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CELC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CELC Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$327.6M9 sales · 3 insiders
3% of the selling was under pre-arranged trading plans.
2025-12 sold $425K2026-01 sold $2.4M2026-03 sold $331K2026-05 sold $4.8M2026-07 sold $317.8MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jul 14Baker Bros. Advisors LPFormer 10% ownerSale3,100,000$102.50$317.8M
May 4David DalveyDirectorSale plan25,000$140.68$3.5M
May 4Richard E BullerDirectorSale plan9,000$140.46$1.3M
Mar 31Richard E BullerDirectorSale plan3,000$110.27$331K
Jan 27David DalveyDirectorSale plan20,000$120.03$2.4M
Dec 5, 2025Richard E BullerDirectorSale3,000$105.69$317K
Every insider buy and sale for CELC over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CELC insider trades →

From SEC Form 4 filings by CELC's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CELC is in one of them and how their past CELC trades turned out.

CELC in the AI portfolios
Loading…

CELC News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CELC in an article yet. Here's the latest on the wider market.

CELC in the news

CELC Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Aug 26
Who traded CELC · since 2020
Latest 4 filings
$1K – $15KTraded Jun 23, 2020Filed Aug 26, 2021
$1K – $15KTraded Jun 22, 2020Filed Aug 26, 2021
$1K – $15KTraded May 26, 2021Filed Jun 23, 2021
$1K – $15KTraded Jun 18, 2020Filed Mar 5, 2021
PersonTypeAmountTradedFiledDelay
Tom MalinowskiD · NJBuy$1K – $15KJun 23, 2020Aug 26, 2021429 d
Tom MalinowskiD · NJBuy$1K – $15KJun 22, 2020Aug 26, 2021430 d
Tom MalinowskiD · NJSell$1K – $15KMay 26, 2021Jun 23, 202128 d
Tom MalinowskiD · NJBuy$1K – $15KJun 18, 2020Mar 5, 2021260 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Celcuity

Celcuity is a biotechnology company based in Minneapolis, Minnesota, that is developing gedatolisib, an investigational cancer treatment for solid tumors. The drug is given intravenously and works by blocking several parts of the PI3K, AKT and mTOR signaling pathway that tumors use to grow and survive. The company's main studies focus on advanced breast cancer and metastatic prostate cancer, and its drug is still in clinical trials and under regulatory review.

Headquarters
Minneapolis, MN